Si-Bone Inc logo

Si-Bone Inc(SIBN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
Consider higher Upturn Star rating
BUY for 25 days
PROFIT SINCE LAST BUY
+16.62% ▲
LAST CLOSE
$23.44
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SIBN

11/13/2026: SIBN (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Si-Bone Inc is a medical device company focused on providing minimally invasive surgical solutions for sacroiliac joint disorders. The company has a leading position in this specialized market, supported by strong clinical evidence and a robust physician training program that drives procedure adoption. Its primary growth story revolves around continued market penetration and the expansion of its product portfolio into broader spinal and pelvic fixation segments. Key risks include intense competition from larger medical device companies, dependence on insurance reimbursement, and the need to scale operations profitably. The stock may best suit growth investors interested in the orthopedic device sector.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company operates in a growing niche of the spine market with scalable technology.
Momentum investorMixed fitInvestment depends on positive clinical and sales momentum, which is sensitive to market conditions.
Value investorWeak fitThe company's focus on R&D and growth over current earnings makes it less suitable for value-based metrics.
Dividend investorWeak fitSi-Bone does not pay dividends and retains all capital for business expansion.
Low-risk investorWeak fitThe stock exhibits volatility typical of mid-cap growth companies in the medical device sector.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock's growth-dependent valuation makes it prone to significant price swings.
Valuation riskMedium / highInvestors pay for future growth, which requires consistent execution to justify the premium.
Competition risk (Large medical device peers)Medium / highLarger companies with extensive distribution networks may pressure Si-Bone's market share.
Business qualityMediumWhile the technology is well-regarded, the business is still building sustainable scale.
Dividend incomeLow / noneThis is a growth-oriented company that does not provide income to investors.
Execution riskMediumOngoing physician training and adoption are critical to maintaining growth momentum.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.06B USD
Price to earnings Ratio -
1Y Target Price 26.78
Price to earnings Ratio -
1Y Target Price 26.78
Volume (30-day avg) 824.8K shares
Beta 0.62
52 Weeks Range 11.48 - 25.92
Updated Date 11/13/2026
52 Weeks Range 11.48 - 25.92
Updated Date 11/13/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.3

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -20.8%
Avg. Invested days 29
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SIBN receives a 3-star rating, supported by solid company fundamentals, and solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
SIBN has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+38.8%) and solid revenue growth (+20.2%) are partially offset by weak cash generation (FCF margin -4.5%), weak profitability (net margin -9.4%), modest insider ownership of 3.15%.

Financial Health Rating

★★★★★
SIBN's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 80.0%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is SIBN's strongest growth driver at +60.3% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+20.2%, solid) and earnings growth (+38.8%, strong) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 111.0% and approximately 89.7% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 3.15% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

First Light Asset Management, LLC 18.02%
BlackRock Inc 8.15%
Cadian Capital Management LP 7.42%
American Century Companies Inc 5.57%
Brown Advisory Holdings Inc 4.60%

Unit Economics (Per $1K Revenue)

★★★★★
SIBN generates approximately $796 of gross profit, $-111 of operating income, and $-45 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
SIBN has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
US RevenueSale of iFuse implants and related surgical instrumentation.Most revenue comes from surgeons buying the company's implants for their procedures in the United States.
International RevenueDistribution of products in select international markets.International sales represent a smaller, secondary growth area for the company.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 985.57M
Price to Sales(TTM) 4.79
Enterprise Value 985.57M
Price to Sales(TTM) 4.79
Enterprise Value to Revenue 4.47
Enterprise Value to EBITDA -14.15
Shares Outstanding 45.11M
Shares Floating 40.46M
Shares Outstanding 45.11M
Shares Floating 40.46M
Percent Insiders 3.15
Percent Institutions 110.98

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.